(HealthDay News) — For Medicare beneficiaries with prostate cancer, stereotactic body radiation therapy (SBRT) is less expensive than intensity-modulated radiation therapy (IMRT), but is associated with more genitourinary toxicity, according to a study published online March 10 in the Journal of Clinical Oncology.

James B. Yu, MD, from the Yale School of Medicine in New Haven, CT, and colleagues performed a retrospective study to examine the treatment cost to Medicare and the toxicity for SBRT or IMRT as a primary treatment for prostate cancer. Data were collected from a national sample of Medicare beneficiaries aged ≥66 years who were treated during 2008–2011. Each of 1,335 SBRT patients was matched to two IMRT patients (2,670 patients) with similar follow-up.

The researchers found that the mean treatment cost was $13,645 for SBRT and $21,023 for IMRT. Genitourinary toxicity was experienced in the six months after treatment initiation by 15.6% of SBRT patients and 12.6% of IMRT patients (odds ratio, 1.29; P=0.009). A total of 43.9% of SBRT patients and 36.3% of IMRT patients had genitourinary toxicity at 24 months post-treatment initiation (odds ratio, 1.38: P=0.001). Claims indicative of urethritis, urinary incontinence, and/or obstruction accounted for the increase in toxicity.

“Although SBRT was associated with lower treatment costs, there appears to be a greater rate of genitourinary toxicity for patients undergoing SBRT compared with IMRT, and prospective correlation with randomized trials is needed,” the authors write.

Two authors disclosed receiving funding from 21st Century Oncology.

Full Text (subscription or payment may be required)